arrow
T

Tanios Bekaii-Saab

Mayo Clinic
H指数:82
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

淋巴结靶向、mKRAS特异性的两亲性疫苗在胰腺癌中的研究:AMPLIFY-7P随机II期试验

2026-10-230
OAAI
Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study

胆道癌患者接受化疗免疫疗法后的预后分层:一项回顾性多中心真实世界研究

Cancer
IF5.1
2026-09-160
PRE
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma

II期研究: futibatinib联合pembrolizumab治疗FGF19表达型晚期肝细胞癌患者的疗效观察

2026-08-250
OAAI
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial'

对编辑来信的回应:'NALIRIFOX与nab-紫杉醇和吉西他滨在治疗初治转移性胰腺癌老年患者中的比较:关键性NAPOLI 3试验的亚组分析'

2026-07-010
OAAI
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial

Elraglusib与化疗在转移性胰腺导管腺癌中的应用:一项随机对照二期临床试验

2026-04-140
OAAI
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis

Tucatinib联合曲妥珠单抗治疗化疗难治性、HER2阳性、RAS野生型转移性结直肠癌(MOUNTAINEER):最终分析

2026-01-120
OAAI
Optimized dose schedule of rucaparib and liposomal irinotecan/5-fluorouracil in metastatic gastrointestinal cancers: A phase 1 study

rucaparib和脂质体伊立替康/5-氟尿嘧啶在转移性消化道肿瘤中的优化给药方案:一项1期研究

Cancer
IF5.1
2025-11-220
PRE
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers

度伐利尤单抗在晚期胆道癌中的应用:来自多个国际中心大型患者队列的真实世界数据

2025-11-120
OAAI
Evaluating third-line therapies in refractory metastatic colorectal cancer: a systematic review and network meta-analysis

评估难治性转移性结直肠癌的三线疗法:一项系统评价和网络Meta分析

2025-10-280
PRE
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial

与健康相关的生活质量和体力状态:NALIRIFOX与nab-paclitaxel + gemcitabine在治疗初治的转移性胰腺导管腺癌患者中的比较:NAPOLI 3试验结果

2025-08-050
OAAI
Fruquintinib in less pretreated patients: multivariate profile-matching analysis of FRESCO-2 to FRESCO

fruquintinib 在较少预治疗患者中的研究:FRESCO-2 与 FRESCO 的多变量配型匹配分析

2025-07-130
OA